Skip to content

Insulin in Treatment of Diabetes Mellitus With Pregnancy

Insulin Analogue Versus Conventional Premixed Insulin in the Treatment of Diabetes Mellitus With Pregnancy: A Prospective Cohort Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04726631
Enrollment
110
Registered
2021-01-27
Start date
2015-01-01
Completion date
2019-12-01
Last updated
2021-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The prevalence of diabetes melilites is rapidly increasing over years and consequently during pregnancy. In 2017, there were 21.3 million pregnant women who experienced hyperglycemia, of which 86.4% of them were diagnosed with gestational diabetes melilites. Pregnancy in women with diabetes is associated with an intensification in adverse maternal, fetal and perinatal outcomes including spontaneous abortions, congenital malformations, preterm labor, and macrosomia. Several studies have confirmed that poor glycemic control in women with either gestational, type 1 or type 2 diabetes during pregnancy is associated with poor pregnancy outcomes. In the same line, proper glycemic control before, early, and through all pregnancy markedly improves both maternal and fetal outcomes. Insulin therapy is the standard treatment of diabetes melilites with the pregnancy if dietary control and exercise fail. However, insulin therapy has its difficulties like approaches to mimicking postprandial insulin release, providing adequate background insulin, balancing insulin dosage, food, activity, hypoglycemic episodes, overall glycemia. This is always a struggle for doctors and patients and much affecting their lifestyle

Interventions

DRUGBasal insulin analogue

Analogue insulin is a sub-group of human insulin

Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.

DRUGNeutral Protamine Hagedorn

is an intermediate-acting insulin

is a type of short-acting insulin.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Age of 18 - 45 years old, * Women with pre-gestational diabetes. * Those who were under premixed insulin therapy prior to pregnancy. * women pregnant between 14 weeks up to 28 weeks of gestation

Exclusion criteria

* History of recurrent miscarriage * multiple pregnancies * chronic hypertension * severe heart, liver, and kidney disease. * women how got pregnant after assisted reproduction * those with advanced retinopathy, hypersensitivity to insulin. * Women who developed bleeding in early pregnancy and those diagnosed to have any major anomaly during the first-trimester scan.

Design outcomes

Primary

MeasureTime frame
the percentage of maternal glycosylated Hemoglobin6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026